Corient Private Wealth LLC Acquires 10,466 Shares of Quest Diagnostics Incorporated $DGX

Corient Private Wealth LLC lifted its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 40.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 36,613 shares of the medical research company’s stock after acquiring an additional 10,466 shares during the quarter. Corient Private Wealth LLC’s holdings in Quest Diagnostics were worth $6,354,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in DGX. Hsbc Holdings PLC boosted its position in Quest Diagnostics by 6.8% during the fourth quarter. Hsbc Holdings PLC now owns 227,107 shares of the medical research company’s stock valued at $39,488,000 after buying an additional 14,361 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Quest Diagnostics by 119.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 380 shares of the medical research company’s stock worth $66,000 after buying an additional 207 shares during the period. Kera Capital Partners Inc. bought a new stake in shares of Quest Diagnostics in the 4th quarter valued at about $333,000. Virtu Financial LLC bought a new stake in shares of Quest Diagnostics in the 4th quarter valued at about $527,000. Finally, Dean Capital Management boosted its holdings in Quest Diagnostics by 3.2% during the 4th quarter. Dean Capital Management now owns 12,478 shares of the medical research company’s stock valued at $2,165,000 after acquiring an additional 382 shares during the period. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Trading Up 1.6%

DGX opened at $206.33 on Friday. Quest Diagnostics Incorporated has a one year low of $164.65 and a one year high of $213.50. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08. The business has a 50 day simple moving average of $195.46 and a two-hundred day simple moving average of $192.67. The firm has a market capitalization of $22.84 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 2.42 and a beta of 0.59.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period last year, the company earned $1.94 EPS. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Analysts predict that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th will be issued a $0.86 dividend. The ex-dividend date is Wednesday, July 8th. This represents a $3.44 annualized dividend and a yield of 1.7%. Quest Diagnostics’s payout ratio is 38.01%.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. The trade was a 37.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the transaction, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DGX shares. Jefferies Financial Group restated a “buy” rating and set a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Evercore set a $225.00 price objective on Quest Diagnostics in a research note on Tuesday, April 21st. UBS Group raised their target price on shares of Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, April 22nd. Weiss Ratings lowered shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (b)” rating in a report on Wednesday. Finally, Barclays increased their price target on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and an average target price of $216.58.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.